. Overexpression of the epidermal growth factor receptor type 2 (HER2) is a
characteristic feature of a variety of cancers, and HER2 levels in tumors (primary
or metastatic) are often used to screen for patients who would benefit from
anti-HER2 antibody (Ab) therapy (e.g., for breast cancer), to determine the efficacy
of a treatment regimen, or to predict the prognostic outcome for a patient (1). Single-photon emission
computed tomography (SPECT) or gamma planar imaging with 